Orchid Pharma (ORCHPHARMA) Q3 24/25 earnings summary

Executive summary

• Q3 FY25 total income was INR 227 crores with EBITDA at INR 37 crores; nine-month FY25 income reached INR 710 crores, up 15% year-over-year, and EBITDA at INR 115 crores, up from INR 99 crores.

• PAT for nine months improved 26% to INR 78 crores from INR 62 crores year-over-year.

• Q3 FY25 revenue declined by 2% year-over-year, while 9M FY25 revenue grew 14% compared to 9M FY24.

• Board approved unaudited standalone and consolidated financial results for Q3 FY2024-25, with review by statutory auditors and Audit Committee.

• Financials prepared per Ind AS and reviewed by Singhi & Co., with a modified conclusion on standalone and qualified conclusion on consolidated results.

Financial highlights

• Q3 FY25 sales were ₹217 Cr, down from ₹221 Cr in Q3 FY24; 9M FY25 sales were ₹684 Cr, up from ₹602 Cr in 9M FY24.

• Q3 FY25 EBITDA was ₹37 Cr (17% margin), down from ₹43 Cr (19% margin) in Q3 FY24; 9M FY25 EBITDA was ₹115 Cr (17% margin), up from ₹99 Cr (16% margin) in 9M FY24.

• Q3 FY25 PBT and PAT were ₹24 Cr, down from ₹31 Cr in Q3 FY24; 9M FY25 PBT and PAT were ₹78 Cr, up from ₹62 Cr in 9M FY24.

• Standalone Q3 FY25 revenue from operations: ₹21,734.25 lakhs; total income: ₹22,727.97 lakhs.

• Standalone Q3 FY25 net profit: ₹2,390.63 lakhs; nine-month net profit: ₹7,863.47 lakhs.

Outlook and guidance

• Management maintains a long-term 20% growth outlook over a three-year horizon, but does not provide short-term or quarterly guidance.

• Gross margin guidance remains stable at 40% ±2% for the near term.

• Delays in project implementation for Jammu manufacturing facility and Alathur API block due to land acquisition and regulatory processes; completion of land registration for Jammu expected before March 2025.

• AMS division expected to remain EBITDA negative for another year, then turn accretive.

• 7-ACA project water trials targeted for April 2026; cefiderocol India launch expected by December 2026.